AMED Co (ROCO:7575) EBIT: NT$67.9 Mil (TTM As of Dec. 2025)


ROCO:7575 AMED Co Ltd ROCO:7575
52 GF Score
Price NT$18.20
GF Value NT$62.62
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is AMED Co EBIT?

AMED Co ROCO:7575 +4.00% 52 EBIT is NT$67.9 Mil as of Dec. 2025. GuruFocus rates ROCO:7575 with a GF Score™ of 52/100 and a GF Value™ of NT$62.62 (Possible Value Trap). The stock has 8 warning signs investors should review.

AMED Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$46.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$67.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AMED Co's annualized ROC % for the quarter that ended in Dec. 2025 was 7.46%. AMED Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AMED Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 6.67%.

AMED Co  (ROCO:7575) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AMED Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=91.036 * ( 1 - 26.92% )/( (867.366 + 915.983)/ 2 )
=66.5291088/891.6745
=7.46 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1155.029 - 195.32 - ( 103.81 - max(0, 435.666 - 528.009+103.81))
=867.366

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1141.635 - 146.996 - ( 78.656 - max(0, 420.491 - 510.655+78.656))
=915.983

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

AMED Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=92.416/( ( (530.704 + max(192.938, 0)) + (538.225 + max(249.301, 0)) )/ 2 )
=92.416/( ( 723.642 + 787.526 )/ 2 )
=92.416/755.584
=12.23 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(188.015 + 205.343 + 10.67) - (195.32 + 0 + 15.77)
=192.938

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(198.894 + 201.933 + 12.969) - (146.996 + 0 + 17.499)
=249.301

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AMED Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=67.907/1018.202
=6.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AMED Co EBIT Related Terms

AMED Co EBIT Historical Data

* Premium members only.

The historical data trend for AMED Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AMED Co EBIT Chart

AMED Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 75.23 111.57 128.90 93.00 67.91

AMED Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.60 57.41 35.58 21.70 46.21

ROCO:7575 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, AMED Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AMED Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AMED Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AMED Co's EV-to-EBIT falls into.


ROCO:7575
52GF Score
AMED Co Ltd ROCO:7575
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AMED Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$67.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$67.9 Mil mean?
AMED Co (ROCO:7575) has a EBIT of NT$67.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AMED Co.
Is AMED Co's EBIT too high?
AMED Co's current EBIT is NT$67.9 Mil. Overall, AMED Co has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AMED Co's EBIT compare to ISRG and BDX?
AMED Co's EBIT of NT$67.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AMED Co. AMED Co's current EBIT is NT$67.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AMED Co stock overvalued right now?
Based on GuruFocus' analysis, AMED Co (ROCO:7575) is currently considered Possible Value Trap. The stock's GF Value™ is NT$62.62, compared to a current price of NT$18.20 — trading 70.9% below its estimated fair value. The current EBIT is NT$67.9 Mil. AMED Co's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For AMED Co (ROCO:7575), the current EBIT is NT$67.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AMED Co (ROCO:7575) Overvalued in 2026?

Based on GuruFocus' analysis, AMED Co stock appears to be undervalued. The current stock price of NT$18.20 is trading 70.9% below its estimated GF Value™ of NT$62.62. GuruFocus considers AMED Co to be Possible Value Trap.

Key valuation signals for ROCO:7575:

  • EBIT: NT$67.9 Mil
  • GF Value™: NT$62.62 vs. price of NT$18.20 (70.9% below fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the ROCO:7575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AMED Co Business Description

Address No. 14, Wuquan 7th Road, 4th Floor-1, Wugu District, New Taipei, TWN
AMED Co Ltd is fully committed to the research and development of UV photopolymerized hydrogels. It is a professional research and development and manufacturing company of wound dressing materials, providing proper wound care solutions, and marketing the product under the brand of Heli Dressing.
52GF Score

Get the complete analysis for ROCO:7575

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.20
Price
NT$62.62
GF Value